{"schema_version":"secwatch.filing_event.v1","accession":"0001217234-24-000032","form_type":"8-K","ticker":"CDNA","cik":"0001217234","company_name":"CareDx, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.599286+00:00","generated_at":"2026-06-05T08:17:50.665220+00:00","sec_items":["2.02","9.01","7.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CareDx reports FY2023 revenue $280.3M, exceeding guidance; Q4 net loss includes $96.3M patent accrual","bullets":["Full-year revenue $280.3M, down 13% YoY; Testing Services revenue $209.7M, down 20%.","Q4 revenue $65.6M, down 20% YoY; net loss $118.1M, including $96.3M patent infringement accrual.","Non-GAAP net loss per share Q4 $0.17; full-year adjusted EBITDA loss $38.0M.","Cash and marketable securities $235.4M; repurchased 2.9M shares for $27.5M in 2023.","Seeking judicial review of January 2024 jury verdict on patent ‘544; Medicare coverage added for HeartCare and AlloSure Lung."],"urls":{"canonical":"https://secwatch.observer/filing/0001217234-24-000032","json":"https://secwatch.observer/filing/0001217234-24-000032.json","markdown":"https://secwatch.observer/filing/0001217234-24-000032.md","text":"https://secwatch.observer/filing/0001217234-24-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1217234/000121723424000032/0001217234-24-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1217234/000121723424000032/cdna-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:17:50.665220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}